Developer docs
API playgroundTry for free, no card

Search company profiles

Universal Diagnostics

Full company profile

uuid0000pj5

Namestring
Universal Diagnostics
Legal namestring
Universal Diagnostics, S.A.
Websiteurl
universaldx.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Universal Diagnostics, S.A. (operating as Universal DX) is a clinical-stage biotechnology company founded in 2012 and headquartered in Seville, Spain, with additional offices in Madrid, Ljubljana (Slovenia), and Dallas (Texas). The company develops minimally invasive, blood-based diagnostic tests (liquid biopsies) for the early detection of cancer and pre-cancerous lesions. Its core technology is a multi-omics platform that combines methylomics, fragmentomics, and microbiomics with proprietary computational biology and machine learning algorithms trained on cell-free DNA from patient blood samples. The lead product, Signal-C®, is a colorectal cancer and advanced adenoma screening test that has demonstrated 93% sensitivity and 92% specificity for colorectal cancer and 54% sensitivity for advanced adenomas at 92% specificity in clinical studies. The company is conducting an FDA pivotal validation study targeting more than 15,000 patients, with completion expected by mid-2025, and is extending the platform to additional cancer indications including pancreatic (Signal-P), liver (Signal-L), lung (Signal-LU), and gastric (Signal-G).

The business model is currently pre-commercial and centered on clinical validation and regulatory approval. Post-FDA approval, Universal DX plans to commercialize Signal-C in the United States through an exclusive strategic collaboration with Quest Diagnostics, leveraging its laboratory network to reach the average-risk screening population (ages 45-84). Revenue mechanics will follow a per-test diagnostic services model routed through Quest. The company has raised approximately $150 million+ in cumulative funding across 13+ rounds, with a $70 million Series B in November 2023 led by Quest Diagnostics, a Series B extension in August 2024 with Olympus Innovation Ventures, a €20.8 million European Investment Bank facility in February 2025, and a $34.9 million round from SETT in January 2026. Universal DX holds ISO 13485 certification for the development, manufacture, and distribution of multi-omic in-vitro diagnostic devices and operates a clinical network of more than 140 hospitals across 10 countries with more than 14,000 samples recruited.

Customers today are primarily clinical research partners (hospitals, biobanks, academic centers) contributing samples and validation data. The future paying customer base is healthcare providers, gastroenterologists, and integrated health systems ordering Signal-C for average-risk screening populations as an alternative to colonoscopy. Public-segment marketing is event-driven, centered on presentations at DDW, AACR, ASCO GI, ESMO, and EACR, plus peer-reviewed publications and earned media coverage. The company is led by co-founder and CEO Juan Martinez Barea, co-founder and CTO Marko Bitenc, and COO Christian Hense, supported by a 13-member scientific advisory board.

Short descriptiontext

Universal Diagnostics (Universal DX) is a clinical-stage Spanish biotechnology company developing blood-based multi-omics and machine learning tests for early cancer detection, with lead product Signal-C® for colorectal cancer screening. It pursues FDA approval and US distribution via an exclusive strategic collaboration with Quest Diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSevilla, Spain
HQ citystring
Sevilla
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-based cancer detection, liquid biopsy diagnostics, multi-omics cancer screening, colorectal cancer screening, early cancer detection
Industry5 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics (Liquid Biopsy)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeSubscription Recurring
Description

Revenue will be generated through blood-based cancer screening tests (Signal-C® and future multi-cancer platform tests) distributed via the Quest Diagnostics laboratory network following FDA approval. The company is developing multiple cancer detection tests including Signal-C® (colorectal), Signal-P™ (pancreatic), Signal-L™ (liver), Signal-LU™ (lung), and Signal-G™ (gastric).

universaldx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Signal C
Description

Liquid biopsy blood test for colorectal cancer and advanced adenomas detection with 92% sensitivity and 94% specificity

universaldx.com
+4 more records
Core offering1 text field

Universal Diagnostics (Universal DX) develops minimally invasive, blood-based liquid biopsy tests for the early detection of cancer and pre-cancerous lesions. Its lead product, Signal-C®, analyzes cell-free DNA (cfDNA) using a proprietary multi-omics platform that combines methylomics, fragmentomics, and microbiomics with computational biology and machine learning to detect colorectal cancer and advanced adenomas. A pipeline of additional Signal tests targets pancreatic, liver, lung, and gastric cancers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 93% sensitivity for colorectal cancer detection
+3 more records
Product overview1 text field

Universal DX operates as a bioinformatics and multi-omics company developing a Cancer Platform—a set of minimally-invasive, blood-based solutions for early cancer detection. The core platform combines multi-omics analysis (methylomics, fragmentomics, microbiomics) with computational biology and machine learning. The lead product is Signal-C®, a liquid biopsy test for colorectal cancer and Advanced Adenomas detection. The platform is being extended with pipeline products including Signal-P™ (pancreatic), Signal-L™ (liver), Signal-LU™ (lung), and Signal-G™ (gastric) cancers. The company is conducting FDA validation studies for Signal-C® with over 15,000 patients and has established strategic collaboration with Quest Diagnostics for US commercialization.

Product and service5 records
1Signal-C®
CategoryIn-Vitro Diagnostic Device (Cancer Screening)
Description

A liquid biopsy blood test that detects colorectal cancer and advanced adenomas (pre-cancerous lesions) using cell-free DNA (cfDNA) methylation and fragmentation analysis, achieving 93% sensitivity and 92% specificity for colorectal cancer and 54% sensitivity for advanced adenomas. Targeted at average-risk adults aged 45-84 and healthcare providers for non-invasive colorectal cancer screening.

2Signal-P™
CategoryIn-Vitro Diagnostic Device (Cancer Screening)
Description

Blood-based test for pancreatic cancer detection using the multi-omics platform combining methylation, fragmentation, and microbiome analysis with machine learning. Currently in pipeline/proof-of-concept stage.

3Signal-L™
CategoryIn-Vitro Diagnostic Device (Cancer Screening)
Description

Blood-based test for liver cancer detection using the multi-omics platform combining methylation, fragmentation, and microbiome analysis with machine learning. Currently in pipeline/proof-of-concept stage.

4Signal-LU™
CategoryIn-Vitro Diagnostic Device (Cancer Screening)
Description

Blood-based test for lung cancer detection using blood-based methylation analysis combined with the multi-omics platform. Proof-of-concept data has been presented at scientific conferences.

5Signal-G™
CategoryIn-Vitro Diagnostic Device (Cancer Screening)
Description

Blood-based test for gastric/stomach cancer detection using the multi-omics platform combining methylation, fragmentation, and microbiome analysis with machine learning. Currently in pipeline/proof-of-concept stage.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

R&D partner for technology development. Hologic (through Diagenode) is a world-class R&D partner supporting Universal DX\'s multi-omics platform development and cancer detection technology.

Strategic tierCoreTypeOthers
Description

Company was founded on Silicon Valley\'s ideals of technology and development originating from Singularity University, which influenced the company\'s approach to innovation and technology development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Universal Diagnostics

Cancer Diagnostics (Liquid Biopsy)universaldx.com

Universal Diagnostics (Universal DX) is a clinical-stage Spanish biotechnology company developing blood-based multi-omics and machine learning tests for early cancer detection, with lead product Signal-C® for colorectal cancer screening. It pursues FDA approval and US distribution via an exclusive strategic collaboration with Quest Diagnostics.

What Universal Diagnostics does

Universal Diagnostics, S.A. (operating as Universal DX) is a clinical-stage biotechnology company founded in 2012 and headquartered in Seville, Spain, with additional offices in Madrid, Ljubljana (Slovenia), and Dallas (Texas). The company develops minimally invasive, blood-based diagnostic tests (liquid biopsies) for the early detection of cancer and pre-cancerous lesions. Its core technology is a multi-omics platform that combines methylomics, fragmentomics, and microbiomics with proprietary computational biology and machine learning algorithms trained on cell-free DNA from patient blood samples. The lead product, Signal-C®, is a colorectal cancer and advanced adenoma screening test that has demonstrated 93% sensitivity and 92% specificity for colorectal cancer and 54% sensitivity for advanced adenomas at 92% specificity in clinical studies. The company is conducting an FDA pivotal validation study targeting more than 15,000 patients, with completion expected by mid-2025, and is extending the platform to additional cancer indications including pancreatic (Signal-P), liver (Signal-L), lung (Signal-LU), and gastric (Signal-G).

The business model is currently pre-commercial and centered on clinical validation and regulatory approval. Post-FDA approval, Universal DX plans to commercialize Signal-C in the United States through an exclusive strategic collaboration with Quest Diagnostics, leveraging its laboratory network to reach the average-risk screening population (ages 45-84). Revenue mechanics will follow a per-test diagnostic services model routed through Quest. The company has raised approximately $150 million+ in cumulative funding across 13+ rounds, with a $70 million Series B in November 2023 led by Quest Diagnostics, a Series B extension in August 2024 with Olympus Innovation Ventures, a €20.8 million European Investment Bank facility in February 2025, and a $34.9 million round from SETT in January 2026. Universal DX holds ISO 13485 certification for the development, manufacture, and distribution of multi-omic in-vitro diagnostic devices and operates a clinical network of more than 140 hospitals across 10 countries with more than 14,000 samples recruited.

Customers today are primarily clinical research partners (hospitals, biobanks, academic centers) contributing samples and validation data. The future paying customer base is healthcare providers, gastroenterologists, and integrated health systems ordering Signal-C for average-risk screening populations as an alternative to colonoscopy. Public-segment marketing is event-driven, centered on presentations at DDW, AACR, ASCO GI, ESMO, and EACR, plus peer-reviewed publications and earned media coverage. The company is led by co-founder and CEO Juan Martinez Barea, co-founder and CTO Marko Bitenc, and COO Christian Hense, supported by a 13-member scientific advisory board.

Universal Diagnostics firmographics

Firmographics
Name
Universal Diagnostics
Legal name
Universal Diagnostics, S.A.
Website
https://universaldx.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Universal Diagnostics (Universal DX) is a clinical-stage Spanish biotechnology company developing blood-based multi-omics and machine learning tests for early cancer detection, with lead product Signal-C® for colorectal cancer screening. It pursues FDA approval and US distribution via an exclusive strategic collaboration with Quest Diagnostics.
Ownership category
akta.pro rank

Universal Diagnostics industry classification

Industry
Product category
Cancer Diagnostics (Liquid Biopsy)
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays

Keywords

  • Blood-based cancer detection
  • Liquid biopsy diagnostics
  • Multi-omics cancer screening
  • Colorectal cancer screening
  • Early cancer detection

Where Universal Diagnostics is headquartered

Location

Headquarters

HQ city
Sevilla
HQ country
Spain
HQ region
Europe

Offices4 records

Markets served

Universal Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Services: Revenue will be generated through blood-based cancer screening tests (Signal-C® and future multi-cancer platform tests) distributed via the Quest Diagnostics laboratory network following FDA approval. The company is developing multiple cancer detection tests including Signal-C® (colorectal), Signal-P™ (pancreatic), Signal-L™ (liver), Signal-LU™ (lung), and Signal-G™ (gastric).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Universal Diagnostics product offering

Product offering

Core offering

Universal Diagnostics (Universal DX) develops minimally invasive, blood-based liquid biopsy tests for the early detection of cancer and pre-cancerous lesions. Its lead product, Signal-C®, analyzes cell-free DNA (cfDNA) using a proprietary multi-omics platform that combines methylomics, fragmentomics, and microbiomics with computational biology and machine learning to detect colorectal cancer and advanced adenomas. A pipeline of additional Signal tests targets pancreatic, liver, lung, and gastric cancers.

Product overview

Universal DX operates as a bioinformatics and multi-omics company developing a Cancer Platform—a set of minimally-invasive, blood-based solutions for early cancer detection. The core platform combines multi-omics analysis (methylomics, fragmentomics, microbiomics) with computational biology and machine learning. The lead product is Signal-C®, a liquid biopsy test for colorectal cancer and Advanced Adenomas detection. The platform is being extended with pipeline products including Signal-P™ (pancreatic), Signal-L™ (liver), Signal-LU™ (lung), and Signal-G™ (gastric) cancers. The company is conducting FDA validation studies for Signal-C® with over 15,000 patients and has established strategic collaboration with Quest Diagnostics for US commercialization.

Differentiator

Problem solved

Functional benefit

Brands

  • Signal C: Liquid biopsy blood test for colorectal cancer and advanced adenomas detection with 92% sensitivity and 94% specificity
  • Signal-P
  • Signal-L
  • Signal-LU
  • Signal-G

Products and services

  • Signal-C® A liquid biopsy blood test that detects colorectal cancer and advanced adenomas (pre-cancerous lesions) using cell-free DNA (cfDNA) methylation and fragmentation analysis, achieving 93% sensitivity and 92% specificity for colorectal cancer and 54% sensitivity for advanced adenomas. Targeted at average-risk adults aged 45-84 and healthcare providers for non-invasive colorectal cancer screening.
  • Signal-P™ Blood-based test for pancreatic cancer detection using the multi-omics platform combining methylation, fragmentation, and microbiome analysis with machine learning. Currently in pipeline/proof-of-concept stage.
  • Signal-L™ Blood-based test for liver cancer detection using the multi-omics platform combining methylation, fragmentation, and microbiome analysis with machine learning. Currently in pipeline/proof-of-concept stage.
  • Signal-LU™ Blood-based test for lung cancer detection using blood-based methylation analysis combined with the multi-omics platform. Proof-of-concept data has been presented at scientific conferences.
  • Signal-G™ Blood-based test for gastric/stomach cancer detection using the multi-omics platform combining methylation, fragmentation, and microbiome analysis with machine learning. Currently in pipeline/proof-of-concept stage.

Quantifiable outcome

  • 93% sensitivity for colorectal cancer detection
  • +3 more outcomes

Companies that use Universal Diagnostics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Universal Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Universal Diagnostics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Hologic (Diagenode)coreStrategic or Co-development PartnerR&D partner for technology development. Hologic (through Diagenode) is a world-class R&D partner supporting Universal DX\'s multi-omics platform development and cancer detection technology.
  • Singularity UniversitycoreOthersCompany was founded on Silicon Valley\'s ideals of technology and development originating from Singularity University, which influenced the company\'s approach to innovation and technology development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Universal Diagnostics competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Universal Diagnostics social profiles

Digital presence

Universal Diagnostics compliance and trust

Trust signal

Compliance1 record

Universal Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Universal Diagnostics leadership team

Management profile

Number of profiles

Profiles3 records

Universal Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Universal Diagnostics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Universal Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Universal Diagnostics

What does Universal Diagnostics do?

Universal Diagnostics (Universal DX) develops minimally invasive, blood-based liquid biopsy tests for the early detection of cancer and pre-cancerous lesions. Its lead product, Signal-C®, analyzes cell-free DNA (cfDNA) using a proprietary multi-omics platform that combines methylomics, fragmentomics, and microbiomics with computational biology and machine learning to detect colorectal cancer and advanced adenomas. A pipeline of additional Signal tests targets pancreatic, liver, lung, and gastric cancers.

Is Universal Diagnostics a public or private company?

Universal Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Universal Diagnostics founded?

Universal Diagnostics was founded in 2012. It employs 101 to 250 people.

Where is Universal Diagnostics based?

Universal Diagnostics is headquartered in Sevilla, Spain, in the Europe region.

How does Universal Diagnostics make money?

One revenue line is on record: diagnostic Testing Services.

Does Universal Diagnostics have an API?

No public API is recorded for Universal Diagnostics.

What industry is Universal Diagnostics in?

Universal Diagnostics's product category is Cancer Diagnostics (Liquid Biopsy). Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals